Roche’s adjusted operating profit rose by a lower-than-expected 5% in 2025, due to the weakened US dollar, despite the drugmaker reporting strong growth for food allergy medicine Xolair (omalizumab) and multiple sclerosis treatment Ocrevus (ocrelizumab). Core operating profit reached SFr21.8bn ($28.4bn) for the Swiss big pharma company in 2025, slightly down from a market consensus of SFr22bn cited by analysts. Total sales for Roche came in at SFr61.5bn, a 7% change at constant exchange rates (CER). By GlobalData Learn more about Strategic IntelligenceOn 28 January, the US dollar fell to its lowest level in four years. Roche’s diagnostics division’s sales increased by 2% to SFr13.8bn, buoyed by increased demand for pathology and molecular solutions.